| | | |  | | | | | | | | | | | | | | | |  | | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | | | | | | | | | | | | | | | RNAi Therapy & Clinical Trials Sponsored Links - Acuity Pharmaceuticals
 - The company is developing RNAi drugs for the treatment of macular degeneration (AMD) and diabetic retinopathy (DR)
- Alnylam Pharmaceuticals, Inc. - Alnylam was founded by Nobel Laureate Phillip Sharp, Thomas Tuschl et al. The company's current capabilities are supporting the development of Direct RNAi™ therapeutics. These products are designed to be administered directly to sites of diseases in various parts of the body, such as the eye, the brain or the lungs.
- Sirna Therapeutics, Inc - The company's researchers are developing siRNAs targeting the VEG-F (vascular endothelial growth factor) for the treatment of macular degeneration, the leading cause of blindness, and hepatitis C virus.
|
